Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:89-95

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, P. J.
Right arrow Articles by Bloise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, P. J.
Right arrow Articles by Bloise, R.
Related Collections
Right arrow Electrophysiology
Right arrow Clinical genetics
Right arrow Ion channels/membrane transport
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Autonomic, reflex, and neurohumoral control of circulation
Right arrow Gene therapy
Right arrow Genetics of cardiovascular disease

(Circulation. 2001;103:89.)
© 2001 American Heart Association, Inc.


Clinical Investigation and Reports

Genotype-Phenotype Correlation in the Long-QT Syndrome

Gene-Specific Triggers for Life-Threatening Arrhythmias

Peter J. Schwartz, MD; Silvia G. Priori, MD, PhD; Carla Spazzolini, PhD; Arthur J. Moss, MD; G. Michael Vincent, MD; Carlo Napolitano, MD, PhD; Isabelle Denjoy, MD; Pascale Guicheney, MD; Günter Breithardt, MD; Mark T. Keating, MD; Jeffrey A. Towbin, MD; Alan H. Beggs, PhD; Paul Brink, MD; Arthur A. M. Wilde, MD; Lauri Toivonen, MD; Wojciech Zareba, MD, PhD; Jennifer L. Robinson, MS; Katherine W. Timothy, MS; Valerie Corfield, MD; Duangrurdee Wattanasirichaigoon, MD; Clive Corbett, MD; Wilhelm Haverkamp, MD; Eric Schulze-Bahr, MD; Michael H. Lehmann, MD; Ketty Schwartz, MD; Philippe Coumel, MD; Raffaella Bloise, MD

From the Department of Cardiology (P.J.S., C.S., R.B.), Policlinico S. Matteo IRCCS and University of Pavia, Pavia, Italy; Molecular Cardiology Laboratories (S.G.P., C.N.), IRCCS Fondazione "S. Maugeri," Pavia, Italy; Department of Medicine (A.J.M., W.Z., J.L.R.), University of Rochester School of Medicine and Dentistry, Rochester, NY; Department of Medicine (M.V., K.W.T.), University of Utah School of Medicine (Salt Lake City); Service de Cardiologie (I.D., P.C.), Hôpital Lariboisière, Paris, France; INSERM U523 (P.G., K.S.), Institut de Myologie, IFR "Coeur Muscle et Vaisseaux" No. 14, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Medizinische Klinik und Poliklinik (G.B., W.H., E.S.-B.), Innere Medizin C, Kardiologie, and Institute for Arteriosclerosis Research, Westfälische Wilhelms Universität Münster, Münster, Germany; Howard Hughes Medical Institute (M.T.K.), University of Utah, Salt Lake City, Utah; Phoebe Willingham Muzzy Pediatric Molecular Cardiology Laboratory (J.A.T.), Baylor College of Medicine, Texas Children’s Hospital, Houston, Tex; Children’s Hospital (A.H.B., D.W.), Genetic Division, Boston, Mass; Department of Internal Medicine (P.B., V.C., C.C.), University of Stellenbosch and Tygerberg Hospital, Tygerberg, Republic of South Africa; Experimental and Molecular Cardiology Group (A.A.M.W.), Academisch Medisch Centrum Amsterdam, and the Interuniversity Cardiology Institute, the Netherlands; Division of Cardiology (L.T.), Department of Medicine, University of Helsinki, Helsinki, Finland; and Department of Internal Medicine (M.H.L.), University of Michigan School of Medicine (Ann Arbor).

Correspondence to Peter J. Schwartz, MD, Department of Cardiology, Policlinico S Matteo IRCCS, V le Golgi, 19, 27100 Pavia, Italy. E-mail PJQT{at}compuserve.com


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—The congenital long-QT syndrome (LQTS) is caused by mutations on several genes, all of which encode cardiac ion channels. The progressive understanding of the electrophysiological consequences of these mutations opens unforeseen possibilities for genotype-phenotype correlation studies. Preliminary observations suggested that the conditions ("triggers") associated with cardiac events may in large part be gene specific.

Methods and Results—We identified 670 LQTS patients of known genotype (LQT1, n=371; LQT2, n=234; LQT3, n=65) who had symptoms (syncope, cardiac arrest, sudden death) and examined whether 3 specific triggers (exercise, emotion, and sleep/rest without arousal) differed according to genotype. LQT1 patients experienced the majority of their events (62%) during exercise, and only 3% occurred during rest/sleep. These percentages were almost reversed among LQT2 and LQT3 patients, who were less likely to have events during exercise (13%) and more likely to have events during rest/sleep (29% and 39%). Lethal and nonlethal events followed the same pattern. Corrected QT interval did not differ among LQT1, LQT2, and LQT3 patients (498, 497, and 506 ms, respectively). The percent of patients who were free of recurrence with ß-blocker therapy was higher and the death rate was lower among LQT1 patients (81% and 4%, respectively) than among LQT2 (59% and 4%, respectively) and LQT3 (50% and 17%, respectively) patients.

Conclusions—Life-threatening arrhythmias in LQTS patients tend to occur under specific circumstances in a gene-specific manner. These data allow new insights into the mechanisms that relate the electrophysiological consequences of mutations on specific genes to clinical manifestations and offer the possibility of complementing traditional therapy with gene-specific approaches.


Key Words: death, sudden • genetics • ion channels • long-QT syndrome • nervous system, autonomic


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The identification between 1995 and 19961 2 of 3 of the genes responsible for the congenital long-QT syndrome (LQTS)3 4 5 6 and the realization that they all encode ion channels involved in the control of repolarization1 2 fostered the concept that LQTS may represent a unique model for the study of genotype-phenotype correlation in hereditary arrhythmogenic disorders. Interest in this correlation has been further stimulated by the demonstration that the mutations identified in these genes produce either gain or loss of function, resulting in an excess of late inward sodium current or in reduced outward potassium current.1 2 These ionic alterations lengthen action potential duration and explain the prolonged QT interval characteristic of LQTS.

Within months of the identification of the first 2 LQTS genes, HERG and SCN5A, some of the present authors7 reported gene-specific differential degrees of QT interval shortening in response to Na+ channel blockade and to heart rate increases. We also noted a seemingly different pattern in the conditions associated with syncope and cardiac arrest. Specifically, although 6 of 7 LQT3 patients (those with mutations in SCN5A, the cardiac Na+ channel gene) experienced their cardiac events at rest or during sleep, all 5 LQT2 patients (those with mutations in HERG, the gene that encodes the rapid component of the delayed rectifier potassium current [IKr]) experienced their events during emotion or exercise. If confirmed, this finding might have implications for the management of LQTS patients of known genotype. We warned against making extrapolations from such a small study and committed ourselves to test this intriguing observation in a population of symptomatic patients of known genotype that was sufficiently large to allow safe and definitive conclusions. This commitment constitutes the focus of the present study.

The identification in 1996 of KvLQT1, a K+ channel gene that, when coexpressed with minK, produces the slow component of the delayed rectifier potassium current (IKs), allowed us to extend the comparison to LQT1, the LQTS subtype with mutations on KvLQT1.1 2

Here, we report the analysis of the triggers involved in the precipitation of major cardiac events in 670 LQTS patients, all symptomatic and of known genotype, who are of the LQT1, LQT2, and LQT3 subtypes.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
For the present study, we (1) identified patients of known genotype, (2) selected among them those who experienced major cardiac events, and (3) further selected the patients whose cardiac events had been associated with, or triggered by, well-defined conditions.

Patients who were of known genotype but were asymptomatic were not considered for inclusion into the study. Because the same electrophysiological mechanism, torsade de pointes (TdP), of varying duration underlies the tachyarrhythmias of LQTS and because all these tachyarrhythmias have a life-threatening potential, we did not distinguish among syncope, cardiac arrest, or sudden cardiac death in the main analysis. However, we also separately analyzed the lethal events. Data were collected on specifically prepared forms. Whenever possible, direct contacts were established to verify the information; special care was taken for patients with multiple events, and in large part, we followed procedures that have been previously described.8 9

The LQTS International Registry contributed 50% of the patients, and 50% originated mostly from the BIOMED LQTS Research Group but also from individual physicians.

We identified 670 patients of the LQT1, LQT2, and LQT3 subtypes; 418 (62%) had been directly genotyped. The remaining 252 (38%) patients had their genotype attributed with certainty because (1) they were obligate gene carriers or (2) they fulfilled both the rigorous criteria (score >=4) for definite clinical diagnosis of LQTS10 and were first- or second-degree relatives of genotyped patients. The few available LQT5 and LQT6 patients were not included.

Triggers: Definitions and Rationale
For purposes of analysis, we identified 3 distinct conditions, or triggers, associated with the onset of cardiac events: exercise, emotion, and rest or sleep without arousal. The choice of these "classified" triggers was based on the following pathophysiological considerations.

Physical stress, or exercise, is a clear-cut condition without possibility of misinterpretation. It is either witnessed or narrated by the patient. It represents a condition associated with progressively increasing heart rate and with the release of both neural and circulating catecholamines.

The opposite condition is represented by events that occurred during sleep or rest in the presumed absence of any known arousal. This can be established for the survivors, whereas for patients found dead in bed, it is impossible to rule out an arousal before sudden death. However, sleep is not a uniformly quiet state, because periods of REM sleep are associated with abrupt increases in sympathetic activity. Events at rest were included only when the absence of a known arousal was combined with a truly resting condition (eg, lying in bed awake or in an armchair), with the exclusion of television watching, driving, and sitting in school. These events usually occur at relatively long cardiac cycles and with a modest amount of circulating catecholamines.

Between these 2 extremes, we introduced emotional stress, that is, stressful events and arousals that occur during normal daily activities (fear, anger) and arousals that occur at rest or during sleep (sudden noise, startle). This condition is usually characterized by an abrupt neurally mediated release of norepinephrine that occurs while the heart rate is relatively low and without allowance of time for QT adaptation to faster rates.

Several patients (22%) had 2 classified triggers (eg, during exercise and during emotions), and only 2 (0.4%) had 3 triggers. To avoid selection bias, where there were multiple trigger mechanisms, each of the separate triggers was included in the analysis. Sometimes the triggers were unknown or "other" (ie, outside the 3 main conditions), such as during anesthesia, fever, menses, or pregnancy-related events.

The possibilities that lethal events (sudden death and documented cardiac arrest) might differ from syncope in their gene-specific relation to triggers and that the sex effect on the time of occurrence of the first event11 might differ between genotypes were considered. The sex analysis included all patients and all triggers, including those different from the classified ones.

Response to Therapy
The relation observed between genotype and specific triggers also suggested that the response to ß-blockers might be in part gene specific.

Data on therapy were available for 494 patients (74%), which also includes patients who received no treatment (in large part representing the sudden deaths that occurred before diagnosis). The treatment modality used for most patients (n=300) was ß-blockers, and we limited our analysis to those patients (n=271, 90%) for whom precise information was available regarding both therapy and outcome. Patients were not included in this analysis if the dosage of ß-blockers was <=0.5 mg·kg–1·d–1 (n=2) and if therapy had been discontinued for >1 month. We also excluded 2 patients with cardiac arrest in association with a QT-prolonging drug and with non–LQTS-related surgery.

Statistical Analysis
A comparison among the patients of ECG variables was performed using the t test for independent samples and ANOVA with Bonferroni’s correction for multiple comparisons. Differences in other clinical features were assessed by the {chi}2 method and Fisher’s exact test for dichotomous variables. Survival curves that represent cumulative event rates were obtained by using the Kaplan-Meier life-tables and were compared by the log-rank test. Data are given as mean±1 SD, and differences were accepted as significant for P<0.05.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
We determined the genotype of 670 symptomatic LQTS patients (Table 1Down). Table 2Down shows the number of patients with unknown trigger, with >=1 of the 3 classified triggers, and with other nonclassifiable triggers. In 200 cases (30%), it was either not possible to identify with certainty the trigger involved (n=116) or the trigger differed from the 3 main categories chosen for analysis (n=84). Cardiac events were induced by 2 different triggers in only 10% of LQT3 patients compared with 25% of LQT1 patients (P=0.04) and 20% of LQT2 patients (NS). Of clinical relevance, among the 105 patients with 2 triggers, only 2 (2%) had events in "opposite" conditions (ie, exercise and sleep/rest without arousal).


View this table:
[in this window]
[in a new window]
 
Table 1. Demographics


View this table:
[in this window]
[in a new window]
 
Table 2. Genotype, Patients, and Triggers

There was no difference between the triggers for the genotyped patients and for the obligate gene carriers whose genotype had not been documented.

Triggers and Cardiac Events
Figure 1Down shows the relation among the 3 subgroups, the 3 classified triggers, and other triggers. The pattern for LQT1 is very distinctive, with most events (62%) occurring during exercise and only a very small minority (3%) occurring during rest/sleep. This is in sharp contrast with the pattern shown by LQT3 patients, for whom only 13% of the events occurred during exercise and 39% occurred at sleep/rest. LQT2 patients have an intermediate pattern, with only 13% occurring during exercise and most of the remainder (43%) occurring with emotional stress.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 1. Triggers for cardiac events according to 3 genotypes. Numbers in parentheses indicate number of triggers, not number of patients.

The frequency of lethal events (cardiac arrest and sudden death) was affected by the genotype; the rate increased from 28% for LQT1 to 40% for LQT2 to 49% for LQT3 patients. This high mortality rate depends on the noninclusion of asymptomatic patients.

The pattern observed for lethal events was similar to that for all events (ie, including syncope), but it did accentuate the differences between LQT1 versus LQT2 and LQT3. Figure 2Down shows that 68% of lethal events occurred during exercise for LQT1, whereas this never occurred for LQT2 and occurred in only 4% of cases for LQT3 patients. By contrast, 49% and 64% of lethal events occurred during rest/sleep without arousal for LQT2 and LQT3 patients, respectively, whereas this occurred in only 9% of cases for LQT1 patients.



View larger version (34K):
[in this window]
[in a new window]
 
Figure 2. Lethal cardiac events according to 3 classified triggers in 3 genotypes. Numbers in parentheses indicate number of patients.

Specific Triggers
Auditory stimuli were rare (2%) among LQT1 patients and relatively frequent (26%) among LQT2 (P<0.001). They also occurred in LQT3 (7%) less frequently than in LQT2 (P=0.002) but more frequently than in LQT1 (P=0.07) (Table 3Down). Conversely, 80% of the patients with events that occurred after auditory stimuli were LQT2 patients. Of note, in LQT2 patients, most of these events (64%) occurred during sleep.


View this table:
[in this window]
[in a new window]
 
Table 3. Genotype and Specific Triggers

Swimming, as a trigger, was particularly frequent among LQT1 patients; it occurred in 33% of patients with a known trigger (107 of 320). By contrast, it was exceptionally rare (1 of 176, 0.6%) among LQT2 patients and absent among LQT3 patients. Of the patients who experienced cardiac events while swimming, 99% were of LQT1 (Table 3Up).

Corrected QT Duration and Triggers
Corrected QT (QTc) measurements were available for 517 (77%) patients (Figure 3Down). The 3 subgroups have very similar average values; furthermore, LQT1 and LQT2, but not LQT3, female patients have longer durations.



View larger version (45K):
[in this window]
[in a new window]
 
Figure 3. Mean±1 SD duration of QT interval, corrected for heart rate (QTc), among 3 genotypes, and according to sex. Numbers in parentheses indicate patients.

Time to First Event and Genotype
For 626 patients (93%), we knew the exact age at which the first cardiac event occurred. This allowed to generate curves that show the time interval from birth to the first major cardiac event for the 3 subgroups (Figure 4Down). LQT1 patients were the earliest to have symptoms; 54% of them become symptomatic before age 10. By contrast, 50% of LQT2 and LQT3 patients were still asymptomatic at age 16. Figure 4Down reflects that the present study includes only symptomatic patients.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 4. Kaplan-Meier cumulative survival curves showing time interval between birth and first cardiac event (syncope, resuscitated cardiac arrest, sudden death). Numbers in parentheses indicate patients. It is important to remember that figure and study do not include asymptomatic patients. LQT1 vs LQT2, P<0.0001. LQT1 vs LQT3, P=0.0001. LQT3 vs LQT2, P=NS.

We also constructed Kaplan-Meyer time-to-event curves specific for the 3 classified triggers within each genotype (Figure 5Down); they were obviously limited to patients with 1 trigger only. For LQT1 patients through age 8, exercise and emotion occurred at the same time; thereafter, the events triggered by exercise occurred earlier, so by the age of 20, 94% of the patients who were destined to experience events with exercise had them, whereas this was true for only 68% of the patients who were destined to experience episodes during emotional stress. Sleep-related events tended to occur markedly later, and by age 20, 50% of patients still had not experienced a first episode; however, this represents a small subgroup. The patterns for LQT2 and LQT3, despite a similar trend, are less distinct, and the separation between triggers is no longer statistically significant.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 5. Kaplan-Meier cumulative survival curves constructed for 3 classified triggers within each genotype and limited to patients with 1 trigger only. In LQT1, exercise vs sleep, P=0.001. Emotion vs sleep, P=NS. Emotion vs exercise, P=0.01.

Among LQT1 patients, male patients had their first event much earlier than female patients (P<0.0001), with the 2 curves beginning to differentiate by age 5 and remaining well distinct over time (Figure 6Down). Among LQT2 and LQT3 patients, this pattern was just a nonsignificant trend.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 6. Kaplan-Meier cumulative survival curves constructed by sex within each genotype.

ß-Blocker Therapy and Genotype
Of the 162 LQT1 patients treated with ß-blockers and for whom adequate information was available, 131 (81%) had no recurrences (Table 4Down). Among those (19%) with recurrences, there were 7 cardiac arrests/sudden deaths, representing 4% of the population treated and 23% of those with recurrences.


View this table:
[in this window]
[in a new window]
 
Table 4. Genotype and ß-Blocker Therapy

The success rate of ß-blocker therapy, as assessed on the basis of recurrences, was lower among LQT2 (P<0.001) and LQT3 (P=0.05) patients.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
This study demonstrates that life-threatening arrhythmias in LQTS patients do not occur at random and that the probability for these events to occur under specific circumstances varies in a gene-specific manner. The unique dimensions of the study, in terms of the number of patients of known genotype who have also experienced a major cardiac event, ensure the validity of the observations and the possibility of extrapolation of these results to all LQTS patients with mutations on these 3 genes.

The results provide new insights into the mechanisms that relate the molecular abnormalities to the onset of lethal arrhythmias and suggest gene-specific approaches to decrease arrhythmic risk.

Findings and Mechanisms
The first difference that emerges from an examination of the patterns of association between various triggering conditions and genotype is that LQT2 patients are more similar to LQT3 patients than to LQT1 patients. Because both LQT1 and LQT2 patients have mutations of K+ channels, this was initially surprising. The most likely explanation lies in the common denominator for LQT2 and LQT3: the presence of a normal IKs current. IKs is activated by fast heart rates and by catecholamines and shortens ventricular repolarization, thus providing a physiological protection against the possibility of reentrant arrhythmias at fast rates. This may help explain why compared with LQT1 patients, LQT2 and LQT3 patients are at relatively low risk during exercise. This pattern is further accentuated when the analysis is limited to lethal events, and the similarity between LQT2 and LQT3 becomes quite impressive.

Experimental observations12 and preliminary clinical data on QT changes during exercise7 and nighttime13 provide additional explanations for the low risk during exercise and the high risk during sleep of LQT3 patients. A significant reduction in action potential duration during rapid pacing was observed in the cellular model for LQT3 but not in the model that mimics LQT2.12 A potential explanation is available.2 With rapid rates, Na+ accumulates in the cell, lowering the Na+ gradient across the membrane and, consequently, the magnitude of INa. The effect of such a reduction would be negligible during the rising phase of the action potential, when INa is of overwhelming magnitude. However, the plateau INa contribution of the mutant channels is of much smaller magnitude due to delayed inactivation of INa and could be significantly affected by such changes. Of importance, this current operates at a critical time, when the action potential is determined by a delicate balance of small currents.1 2 Thus, a reduction in INa during this phase, as can result from faster heart rates, could shorten action potential duration and, hence, the QT interval.

LQT3 patients tend to have shortened QT intervals, much more than normal, during exercise-induced tachycardia and to have significant QT prolongations at long cycle lengths.7 They also have considerably prolonged QT intervals during nighttime, whereas this seems to happen to a lesser degree for LQT2 patients and not at all for LQT1 patients.13 Confirmation of these preliminary data would help to explain the current findings, including the intriguing propensity of LQT3 patients to experience major arrhythmic events while they are asleep.

LQT1 patients, with malfunctioning IKs channels, are expected to shorten their QT intervals during tachycardia less effectively than normal individuals. The superimposition of a major catecholamine release, as happens during exercise, without a proper QT adaptation (ie, QT shortening), sets the stage for early afterdepolarizations, which may then lead to TdP via reentry. This concept is supported by an experimental model for LQT1 in which IKs blockade greatly enhances the probability of TdP in the presence of catecholamines.14

Among these symptomatic LQT1, LQT2, and LQT3 patients, the QT interval was equally prolonged. The apparent discrepancy from our previous report15 is explained by the fact that it included both symptomatic and asymptomatic patients.

We also extended previous observations on the age and sex dependence of first cardiac events.11 The earlier occurrence of cardiac events among male patients reported for nongenotyped LQTS patients is indeed mostly dependent on LQT1. This trend is present across genotypes but is much less distinct among LQT2 and LQT3 patients, where, at variance with LQT1, the difference between sexes is no longer evident after age 20.

Implications for Clinical Management
These novel findings allow a more tailored approach to the management of LQTS patients on the basis of genotype.

The greater probability of becoming symptomatic under one condition does not exclude the possibility of a cardiac event occurring under different circumstances. Nevertheless, patients of a given genotype are more or less likely to experience cardiac events under well-defined conditions; this can provide guidance for diagnostic procedures and for gene-specific approaches to management. Indeed, 65% of the patients continue to experience their cardiac events under conditions similar to their first classified event.

The critical role of an impairment of IKs in the facilitation of adrenergic-dependent arrhythmias has implications for therapy. Indeed, 88% of LQT1 patients were at risk during conditions of sympathetic hyperactivity, exercise, or emotions. Thus, antiadrenergic interventions were expected to be particularly effective for them. They did very well with ß-blocker therapy; >80% remained free from recurrences, with a total mortality rate of 4%. Only a few LQT1 patients will require therapy other than antiadrenergic intervention.

Most LQT1 patients experience their events during exercise; accordingly, not only should they not engage in competitive sports, like all LQTS patients, but also physical stress should be avoided or limited, compatible with quality of life. Swimming, identified early as an important trigger for LQTS patients16 and recently for LQT1 patients,8 is a major risk factor (triggering an event in 33% of them), and without supervision, swimming should be avoided. Because LQT1 patients are endangered by high heart rates, pacemaker therapy is not advised.

LQT3 patients are at higher risk at longer cycle lengths. This raises concerns, not yet supported by evidence, regarding the use of ß-blockers because of the attendant reduction in heart rate. The prevention of norepinephrine release remains important, but it is effectively and more safely achieved with selective left cardiac sympathetic denervation,17 which does not reduce heart rate.18 LQT3 patients may benefit from pacemakers, which would also allow the safe use of ß-blockers, because their QT interval tends to shorten significantly at faster heart rates; accordingly, recreational physical activity may not have to be withheld, except for those who have already experienced events during exercise. The long-term value of Na+ channel blockers in this group, proposed in 1995,7 remains to be tested. Even though the data regarding therapy for LQT3 patients remain numerically limited, their high mortality rate despite therapy, and particularly at the first episode,5 suggests the consideration of internal cardioverter-defibrillator implantation; the combination with left sympathectomy would reduce the probability of lethal arrhythmias while providing a safety net.

Gene-specific management for LQT2 is more problematic. Suggestions that increases in extracellular K+ concentration may be beneficial are hindered by the difficulties in achieving high [K] with chronic oral therapy. These patients are at a relatively low risk during exercise. The occurrence of cardiac events either at sleep/rest without arousal or during exercise, given the extremely low probability of their occurrence under both conditions, can identify the triggers associated with the highest risk. A comparison with LQT1 patients suggested that auditory stimuli are specific for LQT219 ; our data, which demonstrate their occurrence mostly during sleep, support but also qualify that concept by confirming the high prevalence of auditory stimuli as triggers for LQT2 and by showing their significant role also for LQT3 patients. The experimental prevention with ß-blocker therapy of life-threatening arrhythmias triggered by a loud noise suggests their effectiveness also for LQT2 patients at risk under this specific condition. The efficacy of ß-blockers in LQT2 patients was already proposed.10 Finally, the high risk associated with auditory stimuli makes the removal of telephones and alarm clocks from patient bedrooms advisable.

The cumulative survival curves demonstrate that the age at which LQTS becomes clinically manifest is also gene specific, with LQT1 patients being the youngest to experience cardiac events; 86% of them experience their first episode by age 20. In contrast, symptomatic LQT2 and LQT3 patients are also at risk of the onset of cardiac events later in life. Although data for only symptomatic patients are presented here, when dealing with asymptomatic patients of known genotype, it may now be possible to consider their probability of ever becoming symptomatic on the basis of their age. This allows further refinement in management strategy.

Study Limitations
This study has the limitations that are unavoidable with multiple data sources, such as occurs in any registry or large multicenter studies. Due to organizational complexity, data collection forms were very simple, with only information essential for the present study on triggers. Data on secondary objectives, such as response to therapy, should be regarded as hypothesis generating, and will require specific analysis with additional information. Nevertheless, the very large number of genotyped symptomatic patients allows to safe conclusions to be drawn regarding the main aspects of the study.

Conclusions
This uniquely large cooperative study has allowed us to gather information on an unprecedented number of LQTS patients, all with major cardiac events and all of known genotype. In the investigation of hereditary arrhythmogenic disorders, this is the largest data set ever used for genotype-phenotype correlation studies. It provides definitive evidence for gene-specific differences in the propensity to life-threatening arrhythmias under specific conditions and offers insights into some of the underlying mechanisms. It also provides the rationale for a novel approach toward the prevention of sudden death in LQTS on the basis of the integration of experience-supported therapies (ß-blockers, left cardiac sympathetic denervation, pacemakers, implantable cardioverter-defibrillators) with behavioral recommendations and therapeutic choices dictated by gene-specific considerations.


*    Acknowledgments
 
This work was supported in part by grants NIH HL-33843 and HL-51618, CEE BMH4-CT96-0028, Telethon 1058, PROGRES 4P009D, NHS 95.014, and ICIN project 27. The following investigators have contributed to aspects of the study: MacDonald Dick II, Debra Francovich, Marco Hördt, Pamela S. Karnes, Emanuela H. Locati, Mark Russell, Melvin M. Scheinman, Julia Sunkomat, and Heikki Swan. We are also grateful to Pinuccia De Tomasi for expert editorial support.


*    Footnotes
 
Guest Editor for this article was Douglas P. Zipes, MD, Indiana University School of Medicine, Indianapolis, Ind.

Received June 5, 2000; revision received August 9, 2000; accepted August 14, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. 1. Roden DM, Lazzara R, Rosen MR, et al, for the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation. 1996;94:1996–2012.[Abstract/Free Full Text]

2. Priori SG, Barhanin J, Hauer RNW, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management. Parts I and II Circulation. 1999;99:518–528; part III Circulation. 1999;99:674–681 and Eur Heart J. 1999;20:174–195.[Abstract/Free Full Text]

3. Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975;89:378–390.[Medline] [Order article via Infotrieve]

4. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J. 1985;109:399–411.[Medline] [Order article via Infotrieve]

5. Zareba W, Moss AJ, Schwartz PJ, et al, for the International Long-QT Syndrome Registry Research Group. Influence of the genotype on the clinical course of the long QT syndrome. N Engl J Med. 1998;339:960–965.[Abstract/Free Full Text]

6. Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:597–615.

7. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations on the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92:3381–3386.[Abstract/Free Full Text]

8. Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol. 1999;84:876–879.[Medline] [Order article via Infotrieve]

9. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of ß-blocker therapy in congenital long QT syndrome. Circulation. 2000;101:616–623.[Abstract/Free Full Text]

10. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88:782–784.[Free Full Text]

11. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long QT syndrome: findings from the International LQTS Registry. Circulation. 1998;97:2237–2244.[Abstract/Free Full Text]

12. Priori SG, Napolitano C, Cantù F, et al. Differential response to Na+ channel blockade, ß-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long QT syndrome. Circ Res. 1996;78:1009–1015.[Abstract/Free Full Text]

13. Stramba-Badiale M, Priori SG, Napolitano C, et al. Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep? Ital Heart J. 2000;1:323–328.[Medline] [Order article via Infotrieve]

14. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long QT syndrome: effects of ß-adrenergic agonists and antagonists and sodium channels blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 1998;98:2314–2322.[Abstract/Free Full Text]

15. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929–2934.[Abstract/Free Full Text]

16. Schwartz PJ, Zaza A, Locati E, et al. Stress and sudden death: the case of the long QT syndrome. Circulation. 1991;83(suppl II):II-71–II-80.

17. Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: a worldwide report. Circulation. 1991;84:503–511.[Abstract/Free Full Text]

18. Schwartz PJ, Stone HL. Effects of unilateral stellectomy upon cardiac performance during exercise in dogs. Circ Res. 1979;44:637–645.[Free Full Text]

19. Wilde AAM, Jongbloed RJE, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KvLQT1-related patients (LQTS1). J Am Coll Cardiol. 1999;33:327–332.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
EuropaceHome page
N. Colman, A. Bakker, M. Linzer, J. B. Reitsma, W. Wieling, and A. A.M. Wilde
Value of history-taking in syncope patients: in whom to suspect long QT syndrome?
Europace, July 1, 2009; 11(7): 937 - 943.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. C. Ahrens-Nicklas, C. E. Clancy, and D. J. Christini
Re-evaluating the efficacy of {beta}-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling
Cardiovasc Res, June 1, 2009; 82(3): 439 - 447.
[Abstract] [Full Text] [PDF]


Home page
J Am Board Fam MedHome page
W.-Y. Chuang, Y.-T. Chuang, and K.-C. Ueng
Fourteen-Year Follow-up in a Teenager with Congenital Long QT Syndrome Masquerading as Idiopathic Generalized Epilepsy
J Am Board Fam Med, May 1, 2009; 22(3): 331 - 334.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
R. Shephard and C. Semsarian
Advances in the prevention of sudden cardiac death in the young
Therapeutic Advances in Cardiovascular Disease, April 1, 2009; 3(2): 145 - 155.
[Abstract] [PDF]


Home page
BMJ Case ReportsHome page
I. Iniesta, R. Yotti, and A. Garcia-Pastor
Transient loss of consciousness with convulsions in two young adults with potentially fatal underlying heart disease: syncope versus seizures
BMJ Case Reports, March 20, 2009; 2009(mar19_1): bcr0620080285 - bcr0620080285.
[Abstract] [Full Text]


Home page
CirculationHome page
G. M. Vincent, P. J. Schwartz, I. Denjoy, H. Swan, C. Bithell, C. Spazzolini, L. Crotti, K. Piippo, J.-M. Lupoglazoff, E. Villain, et al.
High Efficacy of {beta}-Blockers in Long-QT Syndrome Type 1: Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of {beta}-Blocker Treatment "Failures"
Circulation, January 20, 2009; 119(2): 215 - 221.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
J.-P. Couderc, S. Kaab, M. Hinterseer, S. McNitt, X. Xia, A. Fossa, B. M. Beckmann, S. Polonsky, and W. Zareba
Baseline Values and Sotalol-Induced Changes of Ventricular Repolarization Duration, Heterogeneity, and Instability in Patients With a History of Drug-Induced Torsades de Pointes
J. Clin. Pharmacol., January 1, 2009; 49(1): 6 - 16.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
S. Nattel
Delayed-rectifier potassium currents and the control of cardiac repolarization: Noble and Tsien 40 years after
J. Physiol., December 15, 2008; 586(24): 5849 - 5852.
[Full Text] [PDF]


Home page
Circ Arrhythmia ElectrophysiolHome page
D. W. Wang, L. Crotti, W. Shimizu, M. Pedrazzini, F. Cantu, P. De Filippo, K. Kishiki, A. Miyazaki, T. Ikeda, P. J. Schwartz, et al.
Malignant Perinatal Variant of Long-QT Syndrome Caused by a Profoundly Dysfunctional Cardiac Sodium Channel
Circ Arrhythmia Electrophysiol, December 1, 2008; 1(5): 370 - 378.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
R. J. Kirk, J. L. Hung, S. R. Horner, and J. T. Perez
Implications of Pharmacogenomics for Drug Development
Experimental Biology and Medicine, December 1, 2008; 233(12): 1484 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. E. Odening, O. Hyder, L. Chaves, L. Schofield, M. Brunner, M. Kirk, M. Zehender, X. Peng, and G. Koren
Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2264 - H2272.
[Abstract] [Full Text] [PDF]


Home page
Circ Arrhythmia ElectrophysiolHome page
Y. Ruan, N. Liu, C. Napolitano, and S. G. Priori
Therapeutic Strategies for Long-QT Syndrome: Does the Molecular Substrate Matter?
Circ Arrhythmia Electrophysiol, October 1, 2008; 1(4): 290 - 297.
[Full Text] [PDF]


Home page
Int J EpidemiolHome page
M. D Tobin, M. Kahonen, P. Braund, T. Nieminen, C. Hajat, M. Tomaszewski, J. Viik, R. Lehtinen, G A. Ng, P. W Macfarlane, et al.
Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations
Int. J. Epidemiol., October 1, 2008; 37(5): 1132 - 1141.
[Abstract] [Full Text] [PDF]


Home page
Cleveland Clinic Journal of MedicineHome page
E. LEVINE, S. Z. ROSERO, A. S. BUDZIKOWSKI, A. J. MOSS, W. ZAREBA, and J. P. DAUBERT
Congenital long QT syndrome: Considerations for primary care physicians
Cleveland Clinic Journal of Medicine, August 1, 2008; 75(8): 591 - 600.
[Abstract] [Full Text] [PDF]


Home page
Circ Arrhythmia ElectrophysiolHome page
A. J. Moss and I. Goldenberg
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients With Long-QT Syndrome
Circ Arrhythmia Electrophysiol, August 1, 2008; 1(3): 219 - 226.
[Full Text] [PDF]


Home page
Circ Arrhythmia ElectrophysiolHome page
G. M. Vincent
Genotyping Has a Minor Role in Selecting Therapy for Congenital Long-QT Syndromes at Present
Circ Arrhythmia Electrophysiol, August 1, 2008; 1(3): 227 - 233.
[Full Text] [PDF]


Home page
Eur Heart JHome page
E. R. Behr, C. Dalageorgou, M. Christiansen, P. Syrris, S. Hughes, M. T. Tome Esteban, E. Rowland, S. Jeffery, and W. J. McKenna
Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families
Eur. Heart J., July 1, 2008; 29(13): 1670 - 1680.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
CirculationHome page
I. Goldenberg, A. J. Moss, D. R. Peterson, S. McNitt, W. Zareba, M. L. Andrews, J. L. Robinson, E. H. Locati, M. J. Ackerman, J. Benhorin, et al.
Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome
Circulation, April 29, 2008; 117(17): 2184 - 2191.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Goldenberg, A. J. Moss, J. Bradley, S. Polonsky, D. R. Peterson, S. McNitt, W. Zareba, M. L. Andrews, J. L. Robinson, M. J. Ackerman, et al.
Long-QT Syndrome After Age 40
Circulation, April 29, 2008; 117(17): 2192 - 2201.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
Heart Rhythm UK Familial Sudden Death Syndromes St
Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement
Heart, April 1, 2008; 94(4): 502 - 507.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. J. Schwartz, E. Vanoli, L. Crotti, C. Spazzolini, C. Ferrandi, A. Goosen, P. Hedley, M. Heradien, S. Bacchini, A. Turco, et al.
Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome.
J. Am. Coll. Cardiol., March 4, 2008; 51(9): 920 - 929.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
M. Chinushi, D. Izumi, K. Iijima, S. Ahara, S. Komura, H. Furushima, Y. Hosaka, and Y. Aizawa
Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome
Europace, February 1, 2008; 10(2): 249 - 255.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. M. Roden
Long-QT Syndrome
N. Engl. J. Med., January 10, 2008; 358(2): 169 - 176.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Chen, M. L. Marquardt, D. J. Tester, K. J. Sampson, M. J. Ackerman, and R. S. Kass
Mutation of an A-kinase-anchoring protein causes long-QT syndrome
PNAS, December 26, 2007; 104(52): 20990 - 20995.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Crotti, C. Spazzolini, P. J. Schwartz, W. Shimizu, I. Denjoy, E. Schulze-Bahr, E. V. Zaklyazminskaya, H. Swan, M. J. Ackerman, A. J. Moss, et al.
The Common Long-QT Syndrome Mutation KCNQ1/A341V Causes Unusually Severe Clinical Manifestations in Patients With Different Ethnic Backgrounds: Toward a Mutation-Specific Risk Stratification
Circulation, November 20, 2007; 116(21): 2366 - 2375.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
P. J. Mohler and X. H. T. Wehrens
Mechanisms of Human Arrhythmia Syndromes: Abnormal Cardiac Macromolecular Interactions
Physiology, October 1, 2007; 22(5): 342 - 350.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Antzelevitch
Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2024 - H2038.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Ruan, N. Liu, R. Bloise, C. Napolitano, and S. G. Priori
Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients
Circulation, September 4, 2007; 116(10): 1137 - 1144.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
N. van Dijk, M. C. Boer, T. De Santo, N. Grovale, A. J.J. Aerts, L. Boersma, and W. Wieling
Daily, weekly, monthly, and seasonal patterns in the occurrence of vasovagal syncope in an older population
Europace, September 1, 2007; 9(9): 823 - 828.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
C. Antzelevitch
Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes
Europace, September 1, 2007; 9(suppl_4): iv4 - iv15.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
T. A. Beery, K. A. Shooner, and D. W. Benson
Neonatal Long QT Syndrome Due to a De Novo Dominant Negative hERG Mutation
Am. J. Crit. Care., July 1, 2007; 16(4): 416 - 412.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. L. Vetter
Clues or Miscues?: How to Make the Right Interpretation and Correctly Diagnose Long-QT Syndrome
Circulation, May 22, 2007; 115(20): 2595 - 2598.
[Full Text] [PDF]


Home page
CirculationHome page
N. W. Taggart, C. M. Haglund;, D. J. Tester, and M. J. Ackerman
Diagnostic Miscues in Congenital Long-QT Syndrome
Circulation, May 22, 2007; 115(20): 2613 - 2620.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. Suto, W. Zhu, A. Chan, and G. J. Gross
IKr and IKs remodeling differentially affects QT interval prolongation and dynamic adaptation to heart rate acceleration in bradycardic rabbits
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1782 - H1788.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Seth, A. J. Moss, S. McNitt, W. Zareba, M. L. Andrews, M. Qi, J. L. Robinson, I. Goldenberg, M. J. Ackerman, J. Benhorin, et al.
Long QT Syndrome and Pregnancy
J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1092 - 1098.
[Abstract] [Full Text] [PDF]


Home page
EDUCATION AND PRACTICEHome page
A. Bell and K. McLeod
Not so funny turns
Arch. Dis. Child. Ed. Pract., February 1, 2007; 92(1): ep7 - ep13.
[Full Text] [PDF]


Home page
CirculationHome page
M. Arnestad, L. Crotti, T. O. Rognum, R. Insolia, M. Pedrazzini, C. Ferrandi, A. Vege, D. W. Wang, T. E. Rhodes, A. L. George Jr, et al.
Prevalence of Long-QT Syndrome Gene Variants in Sudden Infant Death Syndrome
Circulation, January 23, 2007; 115(3): 361 - 367.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
K. S. Stokoe, G. Thomas, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/{Delta} murine hearts modelling long QT syndrome 3
J. Physiol., January 1, 2007; 578(1): 69 - 84.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. Thomas, I. S. Gurung, M. J. Killeen, P. Hakim, C. A. Goddard, M. P. Mahaut-Smith, W. H. Colledge, A. A. Grace, and C. L.-H. Huang
Effects of L-type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3
J. Physiol., January 1, 2007; 578(1): 85 - 97.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Fredj, N. Lindegger, K. J. Sampson, P. Carmeliet, and R. S. Kass
Altered Na+ Channels Promote Pause-Induced Spontaneous Diastolic Activity in Long QT Syndrome Type 3 Myocytes
Circ. Res., November 24, 2006; 99(11): 1225 - 1232.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. L. Tan, A. Bardai, W. Shimizu, A. J. Moss, E. Schulze-Bahr, T. Noda, and A. A. M. Wilde
Genotype-Specific Onset of Arrhythmias in Congenital Long-QT Syndrome: Possible Therapy Implications
Circulation, November 14, 2006; 114(20): 2096 - 2103.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Schulze-Bahr
Arrhythmia Predisposition: Between Rare Disease Paradigms and Common Ion Channel Gene Variants
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A67 - A78.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. J. Heradien, A. Goosen, L. Crotti, G. Durrheim, V. Corfield, P. A. Brink, and P. J. Schwartz
Does Pregnancy Increase Cardiac Risk for LQT1 Patients With the KCNQ1-A341V Mutation?
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1410 - 1415.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
C.-u. Choe, E. Schulze-Bahr, A. Neu, J. Xu, Z. I. Zhu, K. Sauter, R. Bahring, S. Priori, P. Guicheney, G. Monnig, et al.
C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3{epsilon}
Hum. Mol. Genet., October 1, 2006; 15(19): 2888 - 2902.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
M. A. Perhonen, P. Haapalahti, S. Kivisto, A.-M. Hekkala, H. Vaananen, H. Swan, and L. Toivonen
Effect of physical training on ventricular repolarization in type 1 long QT syndrome: a pilot study in asymptomatic carriers of the G589D KCNQ1 mutation
Europace, October 1, 2006; 8(10): 894 - 898.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Stengl, C. Ramakers, D. W. Donker, A. Nabar, A. V. Rybin, R. L.H.M.G. Spatjens, T. van der Nagel, W. K.W.H. Wodzig, K. R. Sipido, G. Antoons, et al.
Temporal patterns of electrical remodeling in canine ventricular hypertrophy: Focus on IKs downregulation and blunted {beta}-adrenergic activation
Cardiovasc Res, October 1, 2006; 72(1): 90 - 100.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Goldenberg, J. Mathew, A. J. Moss, S. McNitt, D. R. Peterson, W. Zareba, J. Benhorin, L. Zhang, G. M. Vincent, M. L. Andrews, et al.
Corrected QT Variability in Serial Electrocardiograms in Long QT Syndrome: The Importance of the Maximum Corrected QT for Risk Stratification
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1047 - 1052.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. T. Locati
QT Interval Duration Remains a Major Risk Factor in Long QT Syndrome Patients
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1053 - 1055.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Viitasalo, L. Oikarinen, H. Swan, H. Vaananen, J. Jarvenpaa, H. Hietanen, J. Karjalainen, and L. Toivonen
Effects of Beta-Blocker Therapy on Ventricular Repolarization Documented by 24-h Electrocardiography in Patients With Type 1 Long-QT Syndrome
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 747 - 753.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Quaglini, C. Rognoni, C. Spazzolini, S. G. Priori, S. Mannarino, and P. J. Schwartz
Cost-effectiveness of neonatal ECG screening for the long QT syndrome
Eur. Heart J., August 1, 2006; 27(15): 1824 - 1832.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. G. Priori and C. Napolitano
Molecular Underpinning of "Good Luck"
Circulation, August 1, 2006; 114(5): 360 - 362.
[Full Text] [PDF]


Home page
Journal of the American Dental AssociationHome page
J. M. Karp and A. J. Moss
Dental treatment of patients with long QT syndrome
J Am Dent Assoc, May 1, 2006; 137(5): 630 - 637.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. L. Dodge-Kafka, L. Langeberg, and J. D. Scott
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of A-Kinase Anchoring Proteins
Circ. Res., April 28, 2006; 98(8): 993 - 1001.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
A. Anastasakis, C.-M. Kotta, S. Kyriakogonas, B. Wollnik, A. Theopistou, and C. Stefanadis
Phenotype reveals genotype in a Greek long QT syndrome family.
Europace, April 1, 2006; 8(4): 241 - 244.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Vyas, J. Hejlik, and M. J. Ackerman
Epinephrine QT Stress Testing in the Evaluation of Congenital Long-QT Syndrome: Diagnostic Accuracy of the Paradoxical QT Response
Circulation, March 21, 2006; 113(11): 1385 - 1392.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. G. Priori and C. Napolitano
Role of Genetic Analyses in Cardiology: Part I: Mendelian Diseases: Cardiac Channelopathies
Circulation, February 28, 2006; 113(8): 1130 - 1135.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. J. Schwartz, C. Spazzolini, L. Crotti, J. Bathen, J. P. Amlie, K. Timothy, M. Shkolnikova, C. I. Berul, M. Bitner-Glindzicz, L. Toivonen, et al.
The Jervell and Lange-Nielsen Syndrome: Natural History, Molecular Basis, and Clinical Outcome
Circulation, February 14, 2006; 113(6): 783 - 790.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. A. Fossa, T. Wisialowski, and K. Crimin
QT Prolongation Modifies Dynamic Restitution and Hysteresis of the Beat-to-Beat QT-TQ Interval Relationship during Normal Sinus Rhythm under Varying States of Repolarization
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 498 - 506.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
O. Casis, S.-P. Olesen, and M. C. Sanguinetti
Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator
Mol. Pharmacol., February 1, 2006; 69(2): 658 - 665.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. Berecki, J. G. Zegers, Z. A. Bhuiyan, A. O. Verkerk, R. Wilders, and A. C. G. van Ginneken
Long-QT syndrome-related sodium channel mutations probed by the dynamic action potential clamp technique
J. Physiol., January 15, 2006; 570(2): 237 - 250.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Roberts
Genomics and Cardiac Arrhythmias
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 9 - 21.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Viitasalo, L. Oikarinen, H. Swan, K. A. Glatter, H. Vaananen, H. Fodstad, N. Chiamvimonvat, K. Kontula, L. Toivonen, and M. M. Scheinman
Ratio of Late to Early T-Wave Peak Amplitude in 24-h Electrocardiographic Recordings as Indicator of Symptom History in Patients With Long-QT Syndrome Types 1 and 2
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 112 - 120.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. Napolitano, S. G. Priori, P. J. Schwartz, R. Bloise, E. Ronchetti, J. Nastoli, G. Bottelli, M. Cerrone, and S. Leonardi
Genetic Testing in the Long QT Syndrome: Development and Validation of an Efficient Approach to Genotyping in Clinical Practice
JAMA, December 21, 2005; 294(23): 2975 - 2980.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. S. Kaufman
Efficient Genotyping for Congenital Long QT Syndrome
JAMA, December 21, 2005; 294(23): 3027 - 3028.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Viitasalo, L. Oikarinen, H. Swan, K. A. Glatter, H. Vaananen, H. Fodstad, N. Chiamvimonvat, K. Kontula, L. Toivonen, and M. M. Scheinman
Ratio of Late to Early T-Wave Peak Amplitude in 24-h Electrocardiographic Recordings as Indicator of Symptom History in Patients With Long-QT Syndrome Types 1 and 2
J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.07.068v1.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
T. Jespersen, M. Grunnet, and S.-P. Olesen
The KCNQ1 Potassium Channel: From Gene to Physiological Function
Physiology, December 1, 2005; 20(6): 408 - 416.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. S. Ginsburg, M. P. Donahue, and L. K. Newby
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. A. Brink, L. Crotti, V. Corfield, A. Goosen, G. Durrheim, P. Hedley, M. Heradien, G. Geldenhuys, E. Vanoli, S. Bacchini, et al.
Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population
Circulation, October 25, 2005; 112(17): 2602 - 2610.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A. A M Wilde and C. R Bezzina
Genetics of cardiac arrhythmias
Heart, October 1, 2005; 91(10): 1352 - 1358.
[Full Text] [PDF]


Home page
CirculationHome page
L. Crotti, A. L. Lundquist, R. Insolia, M. Pedrazzini, C. Ferrandi, G. M. De Ferrari, A. Vicentini, P. Yang, D. M. Roden, A. L. George Jr, et al.
KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome
Circulation, August 30, 2005; 112(9): 1251 - 1258.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Shimizu
The long QT syndrome: Therapeutic implications of a genetic diagnosis
Cardiovasc Res, August 15, 2005; 67(3): 347 - 356.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. J. Tester and M. J. Ackerman
Sudden infant death syndrome: How significant are the cardiac channelopathies?
Cardiovasc Res, August 15, 2005; 67(3): 388 - 396.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Kaab and E. Schulze-Bahr
Susceptibility genes and modifiers for cardiac arrhythmias
Cardiovasc Res, August 15, 2005; 67(3): 397 - 413.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. C.M. Beaufort-Krol, M. P. van den Berg, A. A.M. Wilde, J. P. van Tintelen, J. W. Viersma, C. R. Bezzina, and M. Th.E. Bink-Boelkens
Developmental Aspects of Long QT Syndrome Type 3 and Brugada Syndrome on the Basis of a Single SCN5A Mutation in Childhood
J. Am. Coll. Cardiol., July 19, 2005; 46(2): 331 - 337.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Temple, P. Frias, J. Rottman, T. Yang, Y. Wu, E. E. Verheijck, W. Zhang, C. Siprachanh, H. Kanki, J. B. Atkinson, et al.
Atrial Fibrillation in KCNE1-Null Mice
Circ. Res., July 8, 2005; 97(1): 62 - 69.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Zhang, D. W. Benson, M. Tristani-Firouzi, L. J. Ptacek, R. Tawil, P. J. Schwartz, A. L. George, M. Horie, G. Andelfinger, G. L. Snow, et al.
Electrocardiographic Features in Andersen-Tawil Syndrome Patients With KCNJ2 Mutations: Characteristic T-U-Wave Patterns Predict the KCNJ2 Genotype
Circulation, May 31, 2005; 111(21): 2720 - 2726.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
R. D. Lane, C. Laukes, F. I. Marcus, M. A. Chesney, L. Sechrest, K. Gear, C. L. Fort, S. G. Priori, P. J. Schwartz, and A. Steptoe
Psychological Stress Preceding Idiopathic Ventricular Fibrillation
Psychosom Med, May 1, 2005; 67(3): 359 - 365.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
J R Skinner
Is there a relation between SIDS and long QT syndrome?
Arch. Dis. Child., May 1, 2005; 90(5): 445 - 449.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
D. J. Tester, L. J. Kopplin, W. Creighton, A. P. Burke, and M. J. Ackerman
Pathogenesis of Unexplained Drowning: New Insights From a Molecular Autopsy
Mayo Clin. Proc., May 1, 2005; 80(5): 596 - 600.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
D. P. Zipes, M. J. Ackerman, N.A. M. Estes III, A. O. Grant, R. J. Myerburg, and G. Van Hare
Task Force 7: Arrhythmias
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1354 - 1363.
[Full Text] [PDF]


Home page
Biol Res NursHome page
T. T. Beery
The Genetics of Cardiac Arrhythmias
Biol Res Nurs, April 1, 2005; 6(4): 249 - 261.
[Abstract] [PDF]


Home page
Circ. Res.Home page
C. Terrenoire, C. E. Clancy, J. W. Cormier, K. J. Sampson, and R. S. Kass
Autonomic Control of Cardiac Action Potentials: Role of Potassium Channel Kinetics in Response to Sympathetic Stimulation
Circ. Res., March 18, 2005; 96(5): e25 - e34.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, P. J.
Right arrow Articles by Bloise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, P. J.
Right arrow Articles by Bloise, R.
Related Collections
Right arrow Electrophysiology
Right arrow Clinical genetics
Right arrow Ion channels/membrane transport
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Autonomic, reflex, and neurohumoral control of circulation
Right arrow Gene therapy
Right arrow Genetics of cardiovascular disease